Palatin Technologies Inc Total Assets
Palatin Technologies Inc total assets. Based on the latest financial reports, Palatin Technologies Inc (PTN) holds total assets worth $3.73 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Palatin Technologies Inc (PTN) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Palatin Technologies Inc (1996–2024)
Total assets of Palatin Technologies Inc from 1996 to 2024. This chart illustrates how Palatin Technologies Inc's total assets have evolved over time, based on quarterly financial data. See Palatin Technologies Inc stock quote for real-time trading data and today's change.
Palatin Technologies Inc - Asset Composition Analysis
Palatin Technologies Inc Total Assets Breakdown (June 2024)
Palatin Technologies Inc total assets breakdown as of June 2024. Palatin Technologies Inc's total assets of $3.73 Million consist of 91.0% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Palatin Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PTN working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Palatin Technologies Inc's current assets represent 91.0% of total assets in 2024, a decrease from 97.5% in 1996.
- Cash Position: Cash and equivalents constituted 88.7% of total assets in 2024, down from 96.5% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Palatin Technologies Inc Competitors by Total Assets
Key competitors of Palatin Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Palatin Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.32 | 1.20 | 21.28 |
| Quick Ratio | 0.32 | 1.20 | 21.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.82 Million | $1.74 Million | $79.66 Million |
Palatin Technologies Inc - Advanced Valuation Insights
This section examines the relationship between Palatin Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.83 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -40.1% |
| Total Assets | $10.74 Million |
| Market Capitalization | $2.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Palatin Technologies Inc's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Palatin Technologies Inc's assets decreased by 40.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Palatin Technologies Inc (1996–2024)
The table below shows the annual total assets of Palatin Technologies Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $10.74 Million | -40.12% |
| 2023-06-30 | $17.94 Million | -50.27% |
| 2022-06-30 | $36.07 Million | -46.40% |
| 2021-06-30 | $67.30 Million | -20.88% |
| 2020-06-30 | $85.05 Million | -18.79% |
| 2019-06-30 | $104.74 Million | +168.44% |
| 2018-06-30 | $39.02 Million | -31.35% |
| 2017-06-30 | $56.83 Million | +414.25% |
| 2016-06-30 | $11.05 Million | -62.50% |
| 2015-06-30 | $29.47 Million | +134.69% |
| 2014-06-30 | $12.56 Million | -49.91% |
| 2013-06-30 | $25.07 Million | +366.02% |
| 2012-06-30 | $5.38 Million | -74.59% |
| 2011-06-30 | $21.17 Million | +70.90% |
| 2010-06-30 | $12.39 Million | -6.14% |
| 2009-06-30 | $13.20 Million | -30.98% |
| 2008-06-30 | $19.12 Million | -55.30% |
| 2007-06-30 | $42.78 Million | +6.83% |
| 2006-06-30 | $40.05 Million | +13.88% |
| 2005-06-30 | $35.17 Million | +44.25% |
| 2004-06-30 | $24.38 Million | +7.30% |
| 2003-06-30 | $22.72 Million | +83.85% |
| 2002-06-30 | $12.36 Million | -13.24% |
| 2001-06-30 | $14.24 Million | +60.31% |
| 2000-06-30 | $8.89 Million | +89.05% |
| 1999-06-30 | $4.70 Million | -27.69% |
| 1998-06-30 | $6.50 Million | -53.90% |
| 1997-06-30 | $14.10 Million | +100.25% |
| 1996-06-30 | $7.04 Million | -- |
About Palatin Technologies Inc
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is… Read more